seniors moment I was having a Seniors moment ;-)
No wonder I could not replicate it today - my excerpt from Ricky's post, not from a press release:
https://www.stockhouse.com/Bullboards/MessageDetail.aspx?p=0&m=30915237&l=0&r=0&s=MDG&t=LIST
Ricky, where do you get this article from? Here's a rough English translation - the juicy bit is at the end:
"Crossing the desert has been painful for many biotechs in Quebec, some tragic, died of thirst along the way. Arriving at the oasis is no less real for others.
Vaccinated by tobacco
Medicago, Quebec is one of those who are drinking in deep financial pit. March 6, it announced an agreement with Mitsubishi Tanebe (MT), a Japanese pharma founded in 1997 after a cascade of mergers and acquisitions. The agreement provides for an initial payment of 33 million to Medicago. MT is a medium-sized pharma announced a net profit of $ 400 000 Canadian in the last quarter.
"This is just the beginning, warns Andy Sheldon, President of Medicago. This is a payment for the first of three projects that we have with MT. It is for us to produce, with our original technology, vaccines in industrial quantities that will then distribute MT. The 33 million are not used to cover the costs of development and production. This is a pure income. Fees will be paid by MT in addition to the payment of 33 million. "
Medicago must convince ordinary tobacco plants to produce viral like particles and encapsulate the course of a lipid micro capsule. The Quebec company has mastered this kind of acrobatics biotechnology. In this case, it is to produce a pseudo rotavirus to serve as vaccine against infant diarrhea, an infection that made terrible havoc in Asia and Africa. Two other vaccines are in development following the agreement with MT. If efforts are successful, similar to the first payments are scheduled.
Medicago faces another technical challenge and this in record time. "The Defense Advanced Research Projects Agency-(DARPA) U.S. urges us to take up the gauntlet in what will be an exciting sprint enough, says Mr Sheldon. This is to produce 10 million doses of a vaccine that I can not say much, by the end of March! "
The nature of the vaccine is kept secret because DARPA's mission is technologically ahead of the enemies of the United States in a potential bacteriological typing.